Spero Therapeutics Inc
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including … Read more
Spero Therapeutics Inc (SPRO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.658x
Based on the latest financial reports, Spero Therapeutics Inc (SPRO) has a cash flow conversion efficiency ratio of 0.658x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($17.42 Million) by net assets ($26.49 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Spero Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Spero Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Spero Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Spero Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Brunel International NV
AS:BRNL
|
0.153x |
|
Econocom Group SA/NV
BR:ECONB
|
-0.130x |
|
Beijing Tongtech Co Ltd
SHE:300379
|
-0.012x |
|
Banque Cantonale Du Jura SA
SW:BCJ
|
-0.204x |
|
Willow Lane Acquisition Corp. Class A Ordinary Shares
NASDAQ:WLAC
|
-0.003x |
|
ACG
F:ACG
|
N/A |
|
China Renaissance Holdings Limited
PINK:CSCHF
|
-0.011x |
|
North Atlantic Energies
PA:NAE
|
-0.040x |
Annual Cash Flow Conversion Efficiency for Spero Therapeutics Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of Spero Therapeutics Inc from 2015 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $46.12 Million | $-23.44 Million | -0.508x | -64.67% |
| 2023-12-31 | $106.89 Million | $-32.99 Million | -0.309x | -203.18% |
| 2022-12-31 | $75.93 Million | $-7.73 Million | -0.102x | +86.03% |
| 2021-12-31 | $88.29 Million | $-64.35 Million | -0.729x | -12.07% |
| 2020-12-31 | $132.04 Million | $-85.87 Million | -0.650x | +3.04% |
| 2019-12-31 | $74.57 Million | $-50.02 Million | -0.671x | -96.11% |
| 2018-12-31 | $115.86 Million | $-39.62 Million | -0.342x | +25.71% |
| 2017-12-31 | $84.96 Million | $-39.11 Million | -0.460x | +89.89% |
| 2016-12-31 | $6.36 Million | $-28.96 Million | -4.553x | -112.18% |
| 2015-12-31 | $-257.00K | $-9.61 Million | 37.385x | -- |